Ashley Leak Bryant1, Erin Coffman2, Brett Phillips3, Xianming Tan4, Elizabeth Bullard5, Rachel Hirschey6, Joshua Bradley5, Antonia V Bennett7, Angela M Stover8, Lixin Song9, Thomas C Shea10, William A Wood10. 1. The University of North Carolina at Chapel Hill, Carrington Hall, CB #7460, Chapel Hill, NC, 27599-7460, USA. ashley_bryant@unc.edu. 2. Department of Nutrition, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, USA. 3. Hemophilia and Thrombosis Center, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, USA. 4. UNC Lineberger Biostatistics Core, The University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599-7460, USA. 5. North Carolina Cancer Hospital, UNC Hospitals, Chapel Hill, USA. 6. The University of North Carolina at Chapel Hill, Carrington Hall, CB #7460, Chapel Hill, NC, 27599-7460, USA. 7. Department of Health Policy and Management, The University of North Carolina at Chapel Hill, Chapel Hill, USA. 8. Department of Health Policy and Management, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, USA. 9. School of Nursing, University of North Carolina at Chapel Hill, Chapel Hill, USA. 10. Division of Hematology/Oncology, The University of North Carolina at Chapel Hill, Chapel Hill, USA.
Abstract
PURPOSE:Patients undergoing ahematopoietic stem cell transplantation (HCT) have varied symptoms during their hospitalization. This study examined whether daily symptom reporting (with electronic patient-reported outcomes [PROs]) in an inpatient bone marrow transplant clinic reduced symptom burden on post-transplant days +7, +10, and +14. METHODS: A prospective, single-institution 1:1 pilot randomized, two-arm study recruited HCTpatients. HCTinpatients (N = 76) reported daily on 16 common symptoms using the PRO version of the Common Terminology for Adverse Events (PRO-CTCAE). Fisher's exact test was used to examine differences in the proportion of patients reporting individual symptoms. Multivariable linear regression modeling was used to examine group differences in peak symptom burden, while controlling for symptom burden at baseline, age, comorbidity, and transplantation type (autologous or allogeneic). RESULTS:HCTpatients receiving the PRO intervention also experienced lower peak symptom burden (average of 16 symptoms) at days +7, +10, and +14 (10.4 vs 14.5, p = 0.03). CONCLUSIONS: Daily use of electronic symptom reporting to nurses in an inpatient bone marrow transplant clinic reduced peak symptom burden and improved individual symptoms during the 2 weeks post-transplant. A multi-site trial is warranted to demonstrate the generalizability, efficacy, and value of this intervention. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT02574897.
RCT Entities:
PURPOSE:Patients undergoing a hematopoietic stem cell transplantation (HCT) have varied symptoms during their hospitalization. This study examined whether daily symptom reporting (with electronic patient-reported outcomes [PROs]) in an inpatient bone marrow transplant clinic reduced symptom burden on post-transplant days +7, +10, and +14. METHODS: A prospective, single-institution 1:1 pilot randomized, two-arm study recruited HCT patients. HCT inpatients (N = 76) reported daily on 16 common symptoms using the PRO version of the Common Terminology for Adverse Events (PRO-CTCAE). Fisher's exact test was used to examine differences in the proportion of patients reporting individual symptoms. Multivariable linear regression modeling was used to examine group differences in peak symptom burden, while controlling for symptom burden at baseline, age, comorbidity, and transplantation type (autologous or allogeneic). RESULTS: HCT patients receiving the PRO intervention also experienced lower peak symptom burden (average of 16 symptoms) at days +7, +10, and +14 (10.4 vs 14.5, p = 0.03). CONCLUSIONS: Daily use of electronic symptom reporting to nurses in an inpatient bone marrow transplant clinic reduced peak symptom burden and improved individual symptoms during the 2 weeks post-transplant. A multi-site trial is warranted to demonstrate the generalizability, efficacy, and value of this intervention. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT02574897.
Authors: R D Nipp; A El-Jawahri; M Ruddy; C Fuh; B Temel; S M D'Arpino; B J Cashavelly; V A Jackson; D P Ryan; E P Hochberg; J A Greer; J S Temel Journal: Ann Oncol Date: 2019-02-01 Impact factor: 32.976
Authors: Angela K Green; Katherine E Reeder-Hayes; Robert W Corty; Ethan Basch; Mathew I Milowsky; Stacie B Dusetzina; Antonia V Bennett; William A Wood Journal: Oncologist Date: 2015-04-15
Authors: Amylou C Dueck; Tito R Mendoza; Sandra A Mitchell; Bryce B Reeve; Kathleen M Castro; Lauren J Rogak; Thomas M Atkinson; Antonia V Bennett; Andrea M Denicoff; Ann M O'Mara; Yuelin Li; Steven B Clauser; Donna M Bryant; James D Bearden; Theresa A Gillis; Jay K Harness; Robert D Siegel; Diane B Paul; Charles S Cleeland; Deborah Schrag; Jeff A Sloan; Amy P Abernethy; Deborah W Bruner; Lori M Minasian; Ethan Basch Journal: JAMA Oncol Date: 2015-11 Impact factor: 31.777
Authors: Midori Nakagaki; Michael Barras; Cameron Curley; Jason P Butler; Glen A Kennedy Journal: Support Care Cancer Date: 2016-10-13 Impact factor: 3.603
Authors: Ethan Basch; Allison M Deal; Mark G Kris; Howard I Scher; Clifford A Hudis; Paul Sabbatini; Lauren Rogak; Antonia V Bennett; Amylou C Dueck; Thomas M Atkinson; Joanne F Chou; Dorothy Dulko; Laura Sit; Allison Barz; Paul Novotny; Michael Fruscione; Jeff A Sloan; Deborah Schrag Journal: J Clin Oncol Date: 2015-12-07 Impact factor: 44.544
Authors: Margaret F Bevans; Sandra A Mitchell; A John Barrett; Michael Bishop; Richard Childs; Daniel Fowler; Michael Krumlauf; Patricia Prince; Nonniekaye Shelburne; Leslie Wehrlen Journal: Health Qual Life Outcomes Date: 2011-04-17 Impact factor: 3.186
Authors: Chris Gibbons; Ian Porter; Daniela C Gonçalves-Bradley; Stanimir Stoilov; Ignacio Ricci-Cabello; Elena Tsangaris; Jaheeda Gangannagaripalli; Antoinette Davey; Elizabeth J Gibbons; Anna Kotzeva; Jonathan Evans; Philip J van der Wees; Evangelos Kontopantelis; Joanne Greenhalgh; Peter Bower; Jordi Alonso; Jose M Valderas Journal: Cochrane Database Syst Rev Date: 2021-10-12
Authors: Surbhi Sidana; Amylou C Dueck; Gita Thanarajasingam; Joan M Griffin; Carrie Thompson; Urshila Durani; Michelle Burtis; Rahma Warsame; Jonas Paludo; Morie A Gertz; Angela Dispenzieri; Stephen M Ansell; S Vincent Rajkumar; Kathleen Yost; Nora Bennani; Yi Lin; Shaji Kumar Journal: Transplant Cell Ther Date: 2022-05-09
Authors: Sabina De Geest; Sabine Valenta; Lynn Leppla; Alexandra Teynor; Janette Ribaut; Sabine Gerull; Juliane Mielke; Michael Simon; Jana Bartakova; Klaus Kaier; Jens Eckstein Journal: BMC Health Serv Res Date: 2022-08-20 Impact factor: 2.908
Authors: Kaitlyn Lapen; Christopher Sabol; Amy L Tin; Kathleen Lynch; Alyse Kassa; Xiaolin Mabli; John Ford; Elaine Cha; Michael B Bernstein; Lior Z Braunstein; Oren Cahlon; Bobby M Daly; Kiri Sandler; Susan A McCloskey; Andrew J Vickers; Atif J Khan; Erin F Gillespie Journal: Int J Radiat Oncol Biol Phys Date: 2021-07-24 Impact factor: 7.038
Authors: Carrie L Kitko; Joseph Pidala; Hélène M Schoemans; Anita Lawitschka; Mary E Flowers; Edward W Cowen; Eric Tkaczyk; Nosha Farhadfar; Sandeep Jain; Philipp Steven; Zhonghui K Luo; Yoko Ogawa; Michael Stern; Greg A Yanik; Geoffrey D E Cuvelier; Guang-Shing Cheng; Shernan G Holtan; Kirk R Schultz; Paul J Martin; Stephanie J Lee; Steven Z Pavletic; Daniel Wolff; Sophie Paczesny; Bruce R Blazar; Stephanie Sarantopoulos; Gerard Socie; Hildegard Greinix; Corey Cutler Journal: Transplant Cell Ther Date: 2021-04-09